Yousif Capital Management LLC Cuts Stock Holdings in Bruker Corporation $BRKR

Yousif Capital Management LLC reduced its stake in Bruker Corporation (NASDAQ:BRKR) by 2.0% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 32,713 shares of the medical research company’s stock after selling 681 shares during the quarter. Yousif Capital Management LLC’s holdings in Bruker were worth $1,348,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. Pinnacle Bancorp Inc. bought a new stake in shares of Bruker in the 1st quarter worth $29,000. Allworth Financial LP boosted its holdings in Bruker by 92.4% during the first quarter. Allworth Financial LP now owns 758 shares of the medical research company’s stock worth $30,000 after purchasing an additional 364 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its position in Bruker by 1,354.5% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company’s stock worth $33,000 after purchasing an additional 745 shares in the last quarter. Parallel Advisors LLC lifted its position in shares of Bruker by 63.0% during the 2nd quarter. Parallel Advisors LLC now owns 898 shares of the medical research company’s stock worth $37,000 after buying an additional 347 shares in the last quarter. Finally, Annis Gardner Whiting Capital Advisors LLC bought a new position in shares of Bruker during the 1st quarter worth approximately $42,000. 79.52% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director Cynthia M. Friend sold 3,535 shares of the business’s stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $32.25, for a total value of $114,003.75. Following the sale, the director owned 18,016 shares of the company’s stock, valued at $581,016. The trade was a 16.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 27.30% of the stock is currently owned by company insiders.

Bruker Stock Performance

Shares of BRKR stock opened at $38.11 on Tuesday. The firm has a market cap of $5.78 billion, a price-to-earnings ratio of 73.29, a P/E/G ratio of 5.18 and a beta of 1.20. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.70 and a current ratio of 1.61. Bruker Corporation has a 52 week low of $28.53 and a 52 week high of $64.64. The firm’s 50-day simple moving average is $33.63 and its two-hundred day simple moving average is $36.99.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Monday, August 4th. The medical research company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). The company had revenue of $797.40 million during the quarter, compared to the consensus estimate of $811.17 million. Bruker had a return on equity of 17.89% and a net margin of 2.31%.The business’s revenue was down .4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.52 EPS. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. As a group, equities analysts forecast that Bruker Corporation will post 2.69 earnings per share for the current year.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, October 3rd. Stockholders of record on Tuesday, September 23rd were given a $0.05 dividend. The ex-dividend date of this dividend was Tuesday, September 23rd. This represents a $0.20 annualized dividend and a dividend yield of 0.5%. Bruker’s payout ratio is 38.46%.

Analysts Set New Price Targets

A number of analysts recently commented on BRKR shares. Wells Fargo & Company decreased their price target on Bruker from $60.00 to $50.00 and set an “overweight” rating for the company in a research report on Tuesday, August 5th. Barclays reduced their price objective on Bruker from $43.00 to $40.00 and set an “overweight” rating for the company in a research note on Thursday, October 2nd. Bank of America cut their price target on shares of Bruker from $61.00 to $50.00 and set a “buy” rating on the stock in a report on Thursday, June 26th. Weiss Ratings restated a “sell (d+)” rating on shares of Bruker in a research report on Wednesday, October 8th. Finally, Jefferies Financial Group set a $60.00 price objective on shares of Bruker and gave the stock a “buy” rating in a research report on Monday, August 4th. Five analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Bruker presently has an average rating of “Hold” and a consensus target price of $51.00.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.